Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2001-06-04
2004-02-10
Scheiner, Laurie (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S192100, C435S069100, C435S069300, C435S235100
Reexamination Certificate
active
06689366
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to recombinant papillomavirus virus-like particles (VLPs) comprising heterologous neutralizing conformational epitopes. This invention also includes nucleic acids encoding these VLPs and assays employing these synthetic VLPs.
BACKGROUND OF THE INVENTION
Human papillomavirus (HPV) types 6 and 11 are the causative agents for more than 90% of all genital condyloma and laryngeal papillomas. HPV is a DNA virus which is enclosed in a capsid which is made up principally of L1 protein. The L1 proteins of HPV types 6 and 11 are very similar at both the amino acid and nucleotide level. Consequently, it has been difficult to develop assays which reliably distinguish between these two types of infection.
HPV 11 L1 residues Gly
131
-Tyr
132
were previously identified as responsible for the type-specific binding of several HPV 11 neutralizing monoclonal antibodies (Ludmerer et al. 1996. “Two Amino Acid Residues Confer Type Specificity to a Neutralizing, Conformationally Dependent Epitope on Human Papillomavirus Type 11”.
J. Virol
. 70:4791-4794). Within this same work, it was further demonstrated that a substitution at Ser
346
of the HPV 11 L1 sequence dramatically reduced binding of neutralizing monoclonal antibody H11.H3, and that the effect was specific for this antibody. Additional studies demonstrated that several HPV 11 neutralizing antibodies bound to a stretch of the HPV 11 L1 sequence between residues 120-140, whereas H11.H3 bound to a completely distinct site (Ludmerer et al. 1997. “A Neutralizing Epitope of Human Papillomavirus Type 11 is Principally Described by a Continuous Set of Residues Which Overlap a Distinct Linear, Surface-Exposed Epitope”.
J. Virol
. 71:3834-3839).
However, these studies did not define which amino acid residues confer type specificity of binding for antibody H11.H3 completely. Furthermore, there may be other regions of HPV 11 VLPs, not described in these studies, which can elicit important HPV 11-specific, conformationally dependent responses. In addition, VLP-dependent antibodies specific for HPV 6 have also been generated (Christensen et al. 1996 “Monoclonal Antibodies to HPV-6 L1 Virus-Like Particles Identify Conformational and Linear Neutralizing Epitopes on HPV-11 in Addition to Type-Specific Epitopes on HPV-6”.
Virology
224(2):477-486). These antibodies could be useful in evaluation of infectivity by HPV 6. It would be desirable to determine the exact amino acids involved in the specificity of HPV type 6- and additional type 11-specific conformational epitope formations so that improved assays and vaccines may be developed.
DETAILED DESCRIPTION OF THE INVENTION
This invention is directed to a recombinant papillomavirus L1 protein of a first subtype which comprises a conformational epitope of a papillomavirus L1 protein of a second subtype. Preferably, the L1 protein is part of a virus-like particle (VLP). In some embodiments, the papillomavirus is a human papillomavirus (HPV). In a specific embodiment of this invention, a human papillomavirus L1 protein comprises a heterologous conformational epitope from HPV 6. In another specific embodiment of this invention, a human papillomavirus L1 protein comprises a heterologous conformation epitope from HPV 11.
Another aspect of this invention are nucleic acids encoding these heterologous L1 proteins, particularly DNA.
Another aspect of this invention are assays employing the synthetic virus-like particles.
Another aspect of this invention are vaccines comprising nucleic acids and/or proteins encoded by the nucleic acids, wherein the proteins comprise a heterologous conformational epitope.
REFERENCES:
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5738853 (1998-04-01), Ludmerer et al.
patent: 5795754 (1998-08-01), Ludmerer et al.
patent: 5821087 (1998-10-01), Lowe et al.
patent: 5922588 (1999-07-01), Ludmerer et al.
patent: 5985610 (1999-11-01), Lowy et al.
patent: 6013262 (2000-01-01), Frazer et al.
patent: WO 97 18301 (1997-05-01), None
Ludmerer, et al; Journal of Virology, vol. 70, No. 7, PP 4791-4794, 1996.
Ludmerer, et al; Journal of Virology, vol. 71, PP 3834-3839, 1997 224(2): 477-486, 1996.
Christensen, et al; Virology, 224(2): 477-486, 1996.
Jansen Kathrin U.
Ling Jessica C.
Ludmerer Steven W.
McClements William L.
Wang Xin-Min
Finnegan Alysia A.
Giesser Joanne M.
Merck & Co. , Inc.
Scheiner Laurie
LandOfFree
Synthetic virus like particles with heterologous epitopes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic virus like particles with heterologous epitopes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic virus like particles with heterologous epitopes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3283532